News
OPGN
3.480
-9.85%
-0.380
Weekly Report: what happened at OPGN last week (0513-0517)?
Weekly Report · 1d ago
OPGEN ANNOUNCED 1-FOR-10 REVERSE STOCK SPLIT
Reuters · 5d ago
OPGEN : REVERSE STOCK SPLIT WILL INCREASE MARKET PRICE PER SHARE OF COMMON STOCK IN ORDER TO REGAIN COMPLIANCE WITH NASDAQ
Reuters · 5d ago
Weekly Report: what happened at OPGN last week (0506-0510)?
Weekly Report · 05/13 09:57
GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates
NASDAQ · 05/09 11:20
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/08 21:10
Weekly Report: what happened at OPGN last week (0429-0503)?
Weekly Report · 05/06 10:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Akili stock moved upwards by 70.1% to $0.4 during Tuesday's regular session. Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose 51.83%. Eliem Therapeutics shares rose 50.0% during the regular session to $7.53.
Benzinga · 04/30 16:31
OpGen Entered Into An Agreement To Sell Its Commercial Customer Contracts And Installed Base Of Unyvero Systems To Camtech Pte Ltd For $218,000
OpGen to sell its commercial customer contracts and installed base of Unyvero systems to a Singaporean family office for $218,000. OpGen also offered Camtech the opportunity to acquire its remaining inventory for up to $176,000 in the U.S. The transaction follows the sale of Curetis and Ares Genetics' assets.
Benzinga · 04/29 20:24
Press Release: OpGen Provides Update on Business Operations and Strategic Opportunities
OpGen, Inc. Sells its commercial customer contracts and installed base of Unyvero systems to a Singaporean family office for $218,000. OpGen also offered Camtech the opportunity to acquire its remaining inventory of the systems. The Company is preparing for a potential strategic transaction. The company's subsidiaries have sold assets as part of their insolvency proceedings.
Dow Jones · 04/29 20:05
OpGen Provides Update on Business Operations and Strategic Opportunities
OpGen, Inc. To sell its commercial customer contracts and installed base of Unyvero systems to a Singaporean family office for $218,000. The transaction follows Camtech’s prior acquisition of all of Curetis' assets, rights and businesses.
Barchart · 04/29 15:05
Weekly Report: what happened at OPGN last week (0422-0426)?
Weekly Report · 04/29 10:02
OPGEN RECEIVES NASDAQ NOTICE REGARDING DELAYED FORM 10-K
Reuters · 04/23 20:15
Weekly Report: what happened at OPGN last week (0415-0419)?
Weekly Report · 04/22 09:59
OpGen Inc Announces David Lazar as New CEO
TipRanks · 04/17 10:13
OPGEN - ON APRIL 11 ENTERED EMPLOYMENT AGREEMENT WITH DAVID LAZAR POST WHICH LAZAR WILL ACT AS CO'S CHIEF EXECUTIVE OFFICER
Reuters · 04/17 10:03
Weekly Report: what happened at OPGN last week (0408-0412)?
Weekly Report · 04/15 09:54
Weekly Report: what happened at OPGN last week (0401-0405)?
Weekly Report · 04/08 09:56
12 Health Care Stocks Moving In Monday's After-Market Session
OpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. Kyverna Therapeutics shares increased by 9.19%. Galecto and Ontrak also gained ground. Gritstone Bio and Aclarion were among the losers in the market.
Benzinga · 04/01 20:31
OpGen 13D Filing Shows David E. Lazar Reported A 19.9% Stake In The Co As Of March 25, 2024
Benzinga · 04/01 20:12
More
Webull provides a variety of real-time OPGN stock news. You can receive the latest news about Opgen through multiple platforms. This information may help you make smarter investment decisions.
About OPGN
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.